Clinical Observation of Bevacizumab Combined with Chemotherapy in the Treatment of Advanced Gastric Cancer / 中国药房

ABSTRACT

OBJECTIVE:To investigate clinical efficacy and toxic and side effects of bevacizumab combined with chemothera-py in the treatment of advanced gastric cancer. METHODS:84 patients with advanced gastric cancer were randomly divided into combination group and chemotherapy group,with 42 cases in each group. Chemotherapy group received FOLFOX4 chemotherapy regimen(oxaliplatin+calcium folinate+fluorouracil);combination group was additionally given bevacizumab 7.5 mg/kg intravenous-ly,d1,on the basis of chemotherapy. A treatment course lasted for 21 d,and both groups received 3 courses of treatment. The short-term efficacy,the quality improvement of life,serum tumor marker before and after chemotherapy and the toxic and side ef-fects were compared between 2 groups. RESULTS:The effective rate in combination group(57.14%)was significantly higher than chemotherapy group(35.71%),improvement rate of life quality in combination group was higher than chemotherapy group,reduc-tion rate of life quality in combination group was lower than chemotherapy group,the differences were statistically significant(P0.05). CONCLUSIONS:Bevacizumab combined with chemotherapy is effective in the treatment of advanced gastric cancer and don’t increase toxic and side effects.